EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study

Jirui Zhong iD, Xikun Liu, Xuekui Gu, Zenghui Liu

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27093734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Jirui Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Biomarkers, Tumor, src-Family Kinases, Immunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the "Guben" Engineering First-Class Discipline Capacity Improvement Project of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The bone marrow tumor microenvironment (TME) is critical for acute myeloid leukemia (AML) progression, immune evasion, and treatment resistance. SRC, a non-receptor tyrosine kinase involved in multiple oncogenic pathways, has not been systematically characterized in AML in relation to prognosis and immune regulation. We integrated bulk transcriptomic and single-cell RNA-sequencing datasets from TCGA, BeatAML, and GEO. Immune-related targets were identified using xCell-based immune scoring and weighted gene co-expression network analysis (WGCNA), followed by protein–protein interaction analysis and multi-algorithm machine-learning screening. We then evaluated SRC expression patterns, prognostic associations, immune microenvironment features, predicted drug sensitivity, single-cell differentiation dynamics, intercellular communication, and in silico virtual knockout perturbation (scTenifoldKnk). SRC emerged as the most robust hub gene after integration of WGCNA, PPI analysis, machine-learning feature selection, and survival screening. SRC was significantly upregulated in AML compared with normal controls and was independently associated with poor overall survival (HR = 1.231, p = 0.037). High SRC expression was linked to adverse ELN/FAB features, increased immune checkpoint expression, enrichment of inflammatory and immunoregulatory pathways, and a higher proportion of primitive leukemia-associated cell states. Single-cell analyses further suggested that SRC was enriched in CD34+ progenitor compartments, associated with altered cell–cell communication, and accompanied by distinct mutation and pathway profiles. Drug-response prediction and in silico network perturbation analysis further supported the potential biological and translational relevance of SRC-centered programs. SRC is a prognostically relevant and immune-associated hub linked to AML microenvironment remodeling, and may serve as a candidate biomarker and potential therapeutic target that warrants further experimental validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteBiomarkers, Tumorsrc-Family KinasesImmunomodulationHumansPrognosisTumor MicroenvironmentProtein Interaction MapsGene Expression ProfilingMultiomicsGene Regulatory NetworksGene Expression Regulation, LeukemicTranscriptome

Stichwörter der Autor:innen

SRCacute myeloid leukemiabioinformaticsimmunosuppressionprognosistumor microenvironment

Substanzen

Biomarkers, Tumorsrc-Family Kinases

Autor:innen und Institutionen

  • The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
  • Department of Hematology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.

ORCID-Profile: Jirui Zhong

Förderung

  • National Natural Science Foundation of China
  • the "Guben" Engineering First-Class Discipline Capacity Improvement Project of Guangzhou University of Chinese Medicine
  • Guangzhou University of Chinese Medicine

Zitieren

APA

Zhong, J., Liu, X., Gu, X., & Liu, Z. (2026). SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27093734

Vancouver

Zhong J, Liu X, Gu X, Liu Z. SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27093734

BibTeX
@article{Zhong2026,
  author = {Zhong, Jirui and Liu, Xikun and Gu, Xuekui and Liu, Zenghui},
  title = {SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27093734}
}
Kostenlos starten →